Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess performance of medtronic¿s chronic total occlusion (cto) devices: the viance crossing catheter, the enteer re-entry catheter and the enteer guidewire.Survey results are received for an interventional cardiologist with 15 years¿ experience who has been using the viance crossing catheter, the enteer re-entry catheter and the enteer guidewire devices since 2019.The respondent used 30 enteer guidewire devices, 20 viance crossing catheter devices overall, and 30 enteer re-entry catheter devices overall, all within the past 12 months.During use of viance crossing catheter, the respondent reports device related complications of artery spasm (2 events) which were described as constriction of the artery downstream from the catheter, and embolism (3 events) described as distal embolization of plaque fragments with mild ischaemia.Both of these events were reported to be somewhat concerning.
|